NCT05340569Completed
Diagnostic Value of DWI-MRI for Detection of Peritoneal Metastases in High-risk Pancreatic Ductal Adenocarcinoma.
Diagnostic Value of Diffusion-weighted Magnetic Resonance Imaging for Detection of Peritoneal Metastases in High-risk Pancreatic Ductal Adenocarcinoma: a Pilot Study.
Source: ClinicalTrials.gov · Last updated 20 Mar 2025
Brief summary (registry, in English)
Diffusion-weighted magnetic resonance imaging (DWI/MRI) has been described in recent literature as a highly sensitive and specific modality for the detection of peritoneal metastases (PM). It has been demonstrated to be superior to computed tomography (CT) for patients with known peritoneal disease from colorectal and gynaecological malignancies. However, the literature is scarce on the role of DWI/MRI in patients with pancreatic ductal-adenocarcinoma (PDAC). The aim of this study is to prospectively assess the added value of whole-body DWI/MRI (WB-DWI/MRI) to CT for detection of PM in the preoperative staging of patients with high-risk PDAC and evaluate how it correlates with intraoperative findings.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 40 (actual)
- First submitted
- 11 Apr 2022
- Start date
- 28 Mar 2022
- Primary completion date
- 30 Mar 2024
- Lead sponsor
- Laval University
- Diseases
- Pancreatic cancer
- NCT number
- NCT05340569
What you commit to
- Study type: Interventional
- Participants enrolled: 40
- From 28 Mar 2022 to the primary completion date, 30 Mar 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient unfit for pancreatic resection (ECOG 2 or more).
Other illness
- Locally advanced disease on CT.
Other
- Impossibility to obtain tissue diagnosis preoperatively confirming pancreatic ductal adenocarcinoma.
- Tumor size \< 3 cm.
- CA 19-9 \< 400 U/mL or CA 19-9 ≥ 400 U/mL with no preoperative drainage.
- Suspicion of distant metastases, including peritoneal metastases, on CT.
- Patient who is unable to have MRI.
Who the study is looking for
- Confirmed diagnosis of pancreatic ductal adenocarcinoma.
- Resectable disease or borderline resectable disease based on CT.
- Tumor size ≥ 3 cm.
- CA 19-9 ≥ 400 U/mL with normal bilirubin level (\< 40)
- No evidence of distant metastases.
- Patient fit for pancreatic resection (ECOG 0 or 1).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU de Quebec Coordinator of this site? Confirm its status | Québec | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.